Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $27.5900 (-0.11%) ($27.5900 - $27.5900) on Thu. Apr. 1, 2010. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.41% (three month average) | RSI | 46 | Latest Price | $27.5900(-0.11%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV advances 4.5% a day on average for past five trading days. | Weekly Trend | VBIV declines -3.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) GLD(18%) OIH(12%) VWO(12%) EEM(11%) EWG(11%) | Factors Impacting VBIV price | VBIV will decline at least -3.205% in a week (0% probabilities). TLT(-6%) TIP(0%) SHY(2%) LQD(3%) XLU(4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.205% (StdDev 6.41%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $25.77(7.06%) | 10 Day Moving Average | $24.99(10.4%) | 20 Day Moving Average | $26.14(5.55%) | To recent high | -4.1% | To recent low | 136.6% | Market Cap | $6.364b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |